Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

PharmGenHUB

Financiado

Cerrado

Pharmacogenomics Hub in a strengthened IMGGE

Personalized medicine uses pharmacogenomics (PGX) to individualize therapy upon patients’ unique DNA profiles. With ~200,000 deaths/year in Europe due to adverse drug reactions, it has become an imperative to improve treatment. In... ver más

30/06/2025

IMGGE

1M€

Presupuesto del proyecto: 1M€

Líder del proyecto

INSTITUT ZA MOLEKULARNU GENETIKU I GENETICKO... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2022-07-01

HORIZON-WIDERA-2021-ACCESS-02-01: Twinning Western Balkans Special Expected Outcome:The special Twinning call for Western Balkans will contribute to the wide policy in...

Innovación

Cerrada hace 55 años

0% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

Participantes

IMGGE

Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

PharmGenHUB Pharmacogenomics Hub in a strengthened IMGGE 1M€ Cerrado

FIGHTINGDRUGFAILURE Priorities and Standards in Pharmacogenomic Research Opport... 3M€ Cerrado

PDC2021-121243-I00 PLATAFORMA DELFOS: SISTEMA DE INFORMACION PARA LA GESTION DE... 102K€ Cerrado

U-PGx Ubiquitous Pharmacogenomics U PGx Making actionable pharm... 15M€ Cerrado

PREDICTION-ADR Personalisation of tREatment In Cardiovascular disease throu... 4M€ Cerrado

MULTIMOD Multi layer network modules to identify markers for personal... 4M€ Cerrado

Duración del proyecto: 35 meses Fecha Inicio: 2022-07-01
Fecha Fin: 2025-06-30

Líder del proyecto

INSTITUT ZA MOLEKULARNU GENETIKU I GENETICKO... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 1M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Personalized medicine uses pharmacogenomics (PGX) to individualize therapy upon patients’ unique DNA profiles. With ~200,000 deaths/year in Europe due to adverse drug reactions, it has become an imperative to improve treatment. In Western Balkans (WB), individualization of therapy is done sporadically. IMGGE (Institute of Molecular Genetics and Genetic Engineering, University of Belgrade, Serbia) is a pioneer in the PGX in WB. PharmGenHUB will strengthen IMGGE’s PGX R&I potential by exchanging knowledge between IMGGE and EU partnering institutions: University of Patras, Greece (UPAT), University of Ljubljana, Slovenia (UL), University of Trieste, Italy (UNITS). Through collaboration and knowledge sharing with 3 EU partners, IMGGE will become WB central place for PGX diagnostics and R&I, education and trainings, and translation of PGX knowledge into clinically applicable digital solutions. IMGGE’s research project, high-throughput DNA sequencing of WB populations, with support of UPAT and UL, will identify WB specific drug-PGX marker pairs and enable design of electronic tool for better decision-making in clinical practice, electronic PGX assistant for WB (ePGA-WB). iPSC model for validation of novel PGX markers relevant for Europe will be introduced at IMGGE with support of UNITS. IMGGE will renew, reinforce and establish new connections through networking with WB institutions. Project will be realized through short-term visits of IMGGE staff to EU partner institutions, staff exchanges, on-site trainings, experimental laboratory work. Outreach activities will include PGX days, WB conference and joint summer schools. To strengthen research management capacities and administrative skills of IMGGE staff, a research management unit will be established with assistance from UPAT. As focal point of PGX translational research, IMGGE will impact on WB health-care cost benefits and facilitate WB integration to EU-PGX research area through R&I activities and digitalization.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores